贝伐单抗
医学
结直肠癌
肿瘤科
内科学
癌症
化疗
作者
Marinde J. G. Bond,Maarten van Smeden,Koen Degeling,Chiara Cremolini,Hans‐Joachim Schmoll,Carlotta Antoniotti,Sara Lonardi,Sabina Murgioni,Daniele Rossini,Stefan Ibach,Miriam Koopman,Rutger‐Jan Swijnenburg,Cornelis J.A. Punt,Anne M. May,Johannes J.M. Kwakman
摘要
Patient outcomes may differ from randomized trial averages. We aimed to predict benefit from FOLFOXIRI versus infusional fluorouracil, leucovorin, and oxaliplatin/fluorouracil, leucovorin, and irinotecan (FOLFOX/FOLFIRI), both plus bevacizumab, in patients with metastatic colorectal cancer (mCRC).
科研通智能强力驱动
Strongly Powered by AbleSci AI
eric888
cdercder
HEIKU
bc
jyy
OCDer
coolkid
斯寜
无语的安白
Alex
andrele
可千万不要躺平呀
若雨凌风
孙燕
都是
过氧化氢
孳孳为善6387
MchemG
怕孤独的鸽子
AireenBeryl531
皖公网安备34019202002308
